The global In Situ Hybridization Market in terms of revenue was estimated to be worth $1.5 billion in 2022 and is poised to reach $2.8 billion by 2027, growing at a CAGR of 12.6% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
An increase in the adoption of in situ hybridization (ISH) products in managing genetic disorders and cancer patients is set to drive market growth. Emerging economies offer significant opportunities for key market players looking to strengthen their presence. In developed countries, high-quality molecular diagnostic tests are readily available. As a result, emerging markets such as India, China, and Brazil offer significant growth opportunities for MDx-based technology (including ISH) owing to the rising geriatric population, the growing prevalence of infectious diseases, and various types of cancer.
Download a FREE Sample PDF of the Global In Situ Hybridization Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829
Some of the key players in the in situ hybridization market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), Thermofisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US).
The consumables accounted for the largest share of the in situ hybridization industry.
The in situ hybridization market is segmented into consumables, instruments, and software based on product. The ISH consumables segment accounted for the largest share of this market. Robust funding by private and government authorities in cancer research is set to boost the adoption of ISH products. In addition, advent of novel technologies employed in tissue diagnostic protocols and IVD applications is expected to further drive the segment growth through the forecast period..
The DNA FISH technology segment dominated the fluorescent in situ hybridization industry.
Based on the technology, the in situ hybridization market is FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization). The FISH segment is further categorized into DNA FISH, RNA FISH, and PNA FISH. The DNA FISH segment dominated the fluorescent in-situ hybridization market with the highest revenue share. DNA FISH utilizes DNA as a probe to detect the nucleic acid sequence during FISH. DNA FISH is often used in cytogenetics and cancer diagnostics and can detect aberrations in genomes, which result in genetic abnormalities. The FISH procedure's success depends on the genetic material's stability (DNA/RNA). Hence, DNA is preferred over RNA due to the stability acquired from the hydrogen bonds of its double helix structure.
The academic and research institutes have generated the second highest revenue in the in situ hybridization industry.
Based on the end user, the in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. The academic and research institutes generated the second highest revenue in the global market. Academic research laboratories use ISH products for educational purposes, such as understanding the complex processes involved in disease formation. ISH is often used to study different diseases, such as cancer, in which chromosomal abnormalities occur where extra copies of chromosomes are present or a portion of a chromosome is deleted, repeated, or reversed in orientation. Increasing collaborations between pharma, diagnostic companies, and research institutes are expected to drive market growth for this segment.
Direct Purchase of the Global In Situ Hybridization Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=212028829
North America was the largest region of the in situ hybridization industry.
Geographically, the in situ hybridization market is segmented into North America, Europe, Asia Pacific, RoW (Rest of the World). The North American region dominated this market and this dominance is anticipated to continue throughout the forecast period. The US has emerged as the key revenue contributor to this region, with robust public-private funding to develop novel companion diagnostics.
Comments